Literature DB >> 16951173

Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

Ivan V Litvinov1, Donald J Vander Griend, Yi Xu, Lizamma Antony, Susan L Dalrymple, John T Isaacs.   

Abstract

Stage-specific differentiation markers were used to evaluate the cellular composition and the origin of nonimmortalized (PrEC) and immortalized (PZ-HPV7, CA-HPV10, RWPE-1, and 957E/hTERT) human prostate cell lines. These studies documented that immortalized and nonimmortalized prostate epithelial cells established and maintained in low (i.e., <300 micromol/L) Ca(2+) serum-free defined (SFD) medium were all derived from normal nonmalignant prostate tissues and contain CD133(+)/ABCG2(+)/alpha(2)beta(1)(Hi)/p63(-)/PSCA(-)/AR(-)/PSA(-) prostate stem cells. In these cultures, prostate stem cells are able to self-renew and generate two distinct cell lineages: the minor proliferatively quiescent neuroendocrine lineage and the major transit-amplifying cell lineage. Subsequently, CD133(-)/ABCG2(-)/alpha(2)beta(1)(Hi)/p63(+)/PSCA(-)/AR(-)/PSA(-) transit-amplifying cells proliferate frequently and eventually mature into proliferatively quiescent CD133(-)/ABCG2(-)/alpha(2)beta(1)(Lo)/p63(-)/PSCA(+)/AR(-)/PSA(-) intermediate cells. Such proliferatively quiescent intermediate cells, however, do not complete their full maturation into CD133(-)/ABCG2(-)/alpha(2)beta(1)(Lo)/p63(-)/PSCA(-)/AR(+)/PSA(+) luminal-secretory cells in low Ca(2+) SFD medium. Addition of universal type I IFN and synthetic androgen (R1881) to culture medium resulted in up-regulation of androgen receptor protein expression. However, it failed to induce full differentiation of intermediate cells into AR(+)/PSA(+) luminal-secretory cells. Our results indicate that such inability of prostate epithelial cells to complete their differentiation is due to continuous expression of Notch-1 receptor and its downstream effector, Hey-1 protein, which actively suppresses differentiation via its ability to transcriptionally repress a series of genes, including the GATA family of transcription factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951173      PMCID: PMC4124600          DOI: 10.1158/0008-5472.CAN-06-1228

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

Review 2.  Genetic instability and darwinian selection in tumours.

Authors:  D P Cahill; K W Kinzler; B Vogelstein; C Lengauer
Journal:  Trends Cell Biol       Date:  1999-12       Impact factor: 20.808

3.  Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells.

Authors:  Z Basrawala; F Alimirah; H Xin; N Mohideen; S C Campbell; R C Flanigan; D Choubey
Journal:  Oncogene       Date:  2006-05-04       Impact factor: 9.867

4.  Hey1, a mediator of notch signaling, is an androgen receptor corepressor.

Authors:  Borja Belandia; Sue M Powell; Juana M García-Pedrero; Marjorie M Walker; Charlotte L Bevan; Malcolm G Parker
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

5.  Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts.

Authors:  Andreas Fischer; Jürgen Klattig; Burkhard Kneitz; Holger Diez; Manfred Maier; Bettina Holtmann; Christoph Englert; Manfred Gessler
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

6.  p63 regulates commitment to the prostate cell lineage.

Authors:  Sabina Signoretti; Maira M Pires; Meghan Lindauer; James W Horner; Chiara Grisanzio; Sonya Dhar; Pradip Majumder; Frank McKeon; Philip W Kantoff; William R Sellers; Massimo Loda
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-28       Impact factor: 11.205

7.  A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer.

Authors:  C M Perez-Stable; A Pozas; B A Roos
Journal:  Mol Cell Endocrinol       Date:  2000-09-25       Impact factor: 4.102

8.  Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells.

Authors:  Susan Dalrymple; Lizamma Antony; Yi Xu; Aarti R Uzgare; Julia T Arnold; Jurga Savaugeot; Lori J Sokoll; Angelo M De Marzo; John T Isaacs
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

9.  Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.

Authors:  Wendy J Huss; Danny R Gray; Norman M Greenberg; James L Mohler; Gary J Smith
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

10.  Cancer stem cells: an old idea--a paradigm shift.

Authors:  Max S Wicha; Suling Liu; Gabriela Dontu
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

View more
  73 in total

Review 1.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Selective apoptosis induction by the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide is achieved by modulating mitochondrial bioenergetics in premalignant and malignant human prostate epithelial cells.

Authors:  Numsen Hail; Ping Chen; Jadwiga J Kepa
Journal:  Apoptosis       Date:  2009-07       Impact factor: 4.677

3.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Authors:  Donald J Vander Griend; Wouter L Karthaus; Susan Dalrymple; Alan Meeker; Angelo M DeMarzo; John T Isaacs
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 4.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

5.  Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.

Authors:  Ivan V Litvinov; Brendan Cordeiro; Yuanshen Huang; Hanieh Zargham; Kevin Pehr; Marc-André Doré; Martin Gilbert; Youwen Zhou; Thomas S Kupper; Denis Sasseville
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

6.  Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts.

Authors:  Donald J Vander Griend; Yuko Konishi; Angelo M De Marzo; John T Isaacs; Alan K Meeker
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

7.  Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.

Authors:  Ivan V Litvinov; Brendan Cordeiro; Simon Fredholm; Niels Ødum; Hanieh Zargham; Yuanshen Huang; Youwen Zhou; Kevin Pehr; Thomas S Kupper; Anders Woetmann; Denis Sasseville
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 8.  Prostate stem cells and benign prostatic hyperplasia.

Authors:  John T Isaacs
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104

Review 9.  Molecular markers in prostate cancer. Part I: predicting lethality.

Authors:  Sachin Agrawal; William D Dunsmuir
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

10.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Authors:  Paula Sotomayor; Alejandro Godoy; Gary J Smith; Wendy J Huss
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.